Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | ACLY | P53396 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25515229 | 1.00 | ALDH1A1 (0.40) | ALDH1A1CYP2D6ALOX15KMT2AHSD11B1 | |
| SCHEMBL18472629 | 0.89 | CYP2D6 (0.60) | ALDH1A1CYP2D6ALOX15KMT2AHSD11B1 | |
| SCHEMBL5941075 | 0.89 | ALDH1A1 (0.35) | ALDH1A1CYP2D6ALOX15KMT2A | |
| SCHEMBL9613654 | 0.89 | ALDH1A1 (0.35) | ALDH1A1CYP2D6ALOX15KMT2A | |
| SCHEMBL17702738 | 0.83 | ALDH1A1 (0.35) | ALDH1A1KMT2A | |
| SCHEMBL14958851 | 0.83 | ALDH1A1 (0.45) | ALDH1A1ALOX15KMT2A | |
| SCHEMBL17676165 | 0.83 | ALDH1A1 (0.45) | ALDH1A1ALOX15KMT2A | |
| SCHEMBL16722808 | 0.82 | ALDH1A1 (0.31) | ALDH1A1KMT2A | |
| SCHEMBL12279564 | 0.82 | PPARG (0.48) | ALDH1A1CYP2D6ALOX15KMT2A | |
| SCHEMBL19261401 | 0.82 | ALDH1A1 (0.33) | ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | Blaze Bioscience, Inc. | 2023-08-17 | — | — | US | disclosed |
| US-20230211000-A1 | TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | Blaze Bioscience, Inc. | 2023-07-06 | — | — | US | disclosed |
| US-20230151068-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR DISRUPTING TEAD INTERACTIONS | FRED HUTCHINSON CANCER CENTER | 2023-05-18 | — | — | US | disclosed |
| US-11648290-B2 | Cartilage-homing peptides | FRED HUTCHINSON CANCER CENTER (US) | 2023-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648290-B2 | Cartilage-homing peptides | CXCL12, CCL2, MATR3 | ALDH1A1 3797/4885CYP2D6 4800/4885ALOX15 4337/4885 |
| US-20230211000-A1 | TISSUE-HOMING PEPTIDE CONJUGATES AND METHODS OF USE THEREOF | CXCL12, CCL2, CD44 | ALDH1A1 3158/4885CYP2D6 4605/4885ALOX15 3234/4885 |
| US-20230257428-A1 | METHODS OF TREATMENT USING CHLOROTOXIN CONJUGATES | CHLSN, SLC47A1, CLSPN | ALDH1A1 2367/4885CYP2D6 591/4885ALOX15 1877/4885 |
| US-20230151068-A1 | PEPTIDE COMPOSITIONS AND METHODS OF USE THEREOF FOR DISRUPTING TEAD INTERACTIONS | MST1, YAP1, KRAS | ALDH1A1 4808/4885CYP2D6 4851/4885ALOX15 3311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.